Gubra A/S/€GUBRA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Gubra A/S
Gubra A/S is a biotechnology company focused on the research and development of peptide-based therapeutics and innovative technologies for the treatment of obesity, diabetes, and related metabolic disorders. The company's core business includes providing preclinical contract research services with an emphasis on metabolic and fibrotic diseases. Gubra is headquartered in Hørsholm, Denmark. The company emphasizes its expertise in translational models and histology, supporting its unique strategic positioning in the biotech contract research space. By integrating computational biology with experimental data, Gubra aims to deliver comprehensive insights that aid in drug discovery and development.
- Ticker
- €GUBRA
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 330
- Headquarters
- Horsholm, Denmark
- Website
- www.gubra.dk
Gubra A/S Metrics
BasicAdvanced
€653M
-
-€1.49
0.32
-
Price and volume
Market cap
€653M
Beta
0.32
52-week high
€74.85
52-week low
€38.92
Average daily volume
62K
Financial strength
Current ratio
11.424
Quick ratio
10.743
Long term debt to equity
0.151
Total debt to equity
0.178
Interest coverage (TTM)
-2.47%
Profitability
EBITDA (TTM)
-25.637
Gross margin (TTM)
75.29%
Net profit margin (TTM)
-67.25%
Operating margin (TTM)
-73.07%
Effective tax rate (TTM)
-2.50%
Revenue per employee (TTM)
€109,690
Management effectiveness
Return on assets (TTM)
-5.89%
Return on equity (TTM)
-16.12%
Valuation
Price to revenue (TTM)
17.977
Price to book
4.67
Price to tangible book (TTM)
4.74
Price to free cash flow (TTM)
-6.11
Free cash flow yield (TTM)
-16.37%
Free cash flow per share (TTM)
-6.53
Growth
Revenue change (TTM)
-89.72%
Earnings per share change (TTM)
-110.49%
3-year revenue growth (CAGR)
10.02%
3-year earnings per share growth (CAGR)
173.82%
What the Analysts think about Gubra A/S
Analyst ratings (Buy, Hold, Sell) for Gubra A/S stock.
Analyst projections of the future price of Gubra A/S stock.
Bulls say / Bears say
Boehringer Ingelheim has started Phase 2 testing of Gubra-originated BI 3034701, generating a EUR 10 million milestone payment. Its triple-receptor approach offers a differentiated route to treating obesity, although efficacy still needs to be shown in trials. (Gubra)
Gubra’s own GUB-UCN2 has entered a Phase 1/2a trial, testing whether it can reduce fat while preserving or increasing muscle, including in combination with incretin therapy. Success could give the company a differentiated role alongside weight-loss drugs, though this remains an early-stage opportunity. (Gubra)
Group operating loss was DKK 123 million in H1 2026, while biotech costs are forecast at DKK 330–360 million for the full year. The prior-year comparison was boosted by AbbVie’s large upfront payment, highlighting how dependent reported results can be on occasional licensing income. (Gubra)
GUB-UCN2 has no human efficacy results yet; the first data, from the initial single-dose study, are expected in H1 2027. Its proposed muscle-preserving benefit therefore remains unproven, and meaningful evidence will take time to emerge. (Gubra)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
Gubra A/S Financial Performance
Revenues and expenses
Gubra A/S Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.